查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1618644

抗藥性金黃色葡萄球菌治療市場：按藥物類型、給藥途徑和銷售管道分類 - 全球預測 2025-2030

Methicillin-Resistant Staphylococcus Aureus Drugs Market by Agent Type (Ceftaroline, Daptomycin, Linezolid), Route of Administration (Oral, Parenteral), Sales Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗藥性金黃色葡萄球菌治療市場規模為20.9億美元，預計2024年將達22.1億美元，複合年成長率為6.39%，2030年將達32億美元。

抗藥性金黃色葡萄球菌(MRSA) 治療市場專注於針對 MRSA 引起的感染疾病的特定治療，MRSA 是一種對多種抗生素具有抗藥性的葡萄球菌。這些藥物的需求之所以出現，是因為抗甲氧西林金黃色葡萄球菌對公共衛生構成了重大挑戰，因為它對常見抗生素具有抗藥性，導致通常難以治療的嚴重感染疾病。應用涵蓋各種醫療保健環境，包括醫院和門診診所，主要用於治療皮膚感染疾病、肺炎和血液感染疾病。最終用途領域包括醫療保健設施、製藥和生技公司。關鍵的成長要素包括抗生素抗藥性感染疾病的流行和醫療保健支出的增加，而分子診斷和藥物開發的進步推動了進一步的進展。最近的趨勢包括開發新的抗生素和替代療法，例如噬菌體療法和免疫療法。公司應探索與學術機構合作進行藥物發現，並投資人工智慧主導的研究以縮短開發週期。市場開拓的限制包括高昂的藥物開發成本、潛在的監管障礙以及醫療保健系統整合新 MRSA治療方法的適應性緩慢。來自政府和醫療保健提供者的經濟挑戰和價格壓力也發揮著重要作用。可以透過專注於多標靶藥物開發和利用生物技術來提高現有治療方法的有效性來推動創新。此外，加強感染控制和病患教育可以最大限度地減少 MRSA 感染並間接影響市場成長。 MRSA 治療市場的性質是動態的，醫學研究的快速進步導致了不斷變化的格局。研發方面的策略投資以及最尖端科技的採用對於企業站穩腳跟並有效應對 MRSA 帶來的新威脅至關重要。

主要市場統計
基準年[2023] 20.9億美元
預計年份 [2024] 22.1億美元
預測年份 [2030] 32.2億美元
複合年成長率（%） 6.39%

市場動態：快速發展的抗藥性金黃色葡萄球菌治療市場的關鍵市場洞察

供需的動態交互作用正在改變抗藥性金黃色葡萄球菌治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 與抗藥性金黃色葡萄球菌相關的感染疾病日益流行
    • 私營和公共部門增加對醫療保健的投資
  • 市場限制因素
    • 抗藥性金黃色葡萄球菌治療藥物製劑所用原料成本變化
  • 市場機會
    • 正在進行的研發活動，開發新型抗藥性金黃色葡萄球菌治療方法
    • 抗藥性金黃色葡萄球菌治療的專利到期增加
  • 市場挑戰
    • 漫長而嚴格的監管核准流程

波特五力：開拓抗藥性金黃色葡萄球菌治療市場的策略工具

波特的五力架構是了解抗藥性金黃色葡萄球菌治療市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對抗抗藥性金黃色葡萄球菌治療藥物市場的影響

外部宏觀環境因素在塑造抗藥性金黃色葡萄球菌治療市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解抗藥性金黃色葡萄球菌治療藥物市場的競爭格局

對抗藥性金黃色葡萄球菌治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣抗藥性金黃色葡萄球菌治療市場供應商的績效評估

FPNV定位矩陣是評估抗藥性金黃色葡萄球菌治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪抗藥性金黃色葡萄球菌治療市場的成功之路

對於希望加強在全球市場的影響力的公司來說，抗藥性金黃色葡萄球菌治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 抗藥性金黃色葡萄球菌引起的感染疾病盛行率增加
      • 私營和公共部門增加對醫療保健的投資
    • 抑制因素
      • 抗藥性金黃色葡萄球菌治療配方中使用的原料的變動成本
    • 機會
      • 持續研發新開發的抗藥性金黃色葡萄球菌治療藥物
      • 抗藥性金黃色葡萄球菌治療藥物專利到期數量增加
    • 任務
      • 耗時且嚴格的監管核准流程
  • 市場區隔分析
    • 藥物類型：使用Daptomycin有效治療 MRSA 的進展
    • 銷售管道：由於易於訪問，對線上管道的偏好正在增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章抗藥性金黃色葡萄球菌治療藥物市場（按藥物）

  • 頭孢洛林
  • Daptomycin
  • Linezolid
  • 特拉萬辛
  • 萬古黴素

第7章抗藥性金黃色葡萄球菌治療市場：依給藥途徑

  • 口服
  • 胃腸外的

第8章抗藥性金黃色葡萄球菌治療藥物市場：依銷售管道

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第9章 美洲抗藥性金黃色葡萄球菌治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區抗藥性金黃色葡萄球菌治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲抗藥性金黃色葡萄球菌治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 英國政府策略投資全球抗菌藥物抗藥性監測，加強亞洲和非洲的衛生系統
    • 瓦西利亞申請 FDA核准新抗生素頭孢比普羅對抗 MRSA
    • BARDA 為 Melinta Therapeutics 提供策略性資助舉措，以改善兒科抗生素的獲取
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Aridis Pharmaceuticals Inc.
  • Armata Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Basilea Pharmaceutica Ltd.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Cardinal Health, Inc.
  • Cumberland Pharmaceuticals Inc.
  • Debiopharm SA
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Innovation Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Nabriva Therapeutics GMBH
  • Novartis AG
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • R-Biopharm AG
  • Shionogi Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries ltd
  • Theravance Biopharma, Inc.
Product Code: MRR-0363DFE0369A

The Methicillin-Resistant Staphylococcus Aureus Drugs Market was valued at USD 2.09 billion in 2023, expected to reach USD 2.21 billion in 2024, and is projected to grow at a CAGR of 6.39%, to USD 3.22 billion by 2030.

The Methicillin-Resistant Staphylococcus Aureus (MRSA) drugs market focuses on therapeutics specifically designed to combat infections caused by MRSA, a type of staphylococcus bacteria resistant to many antibiotics. The necessity for these drugs arises from the significant challenge MRSA poses to public health due to its resistance to common antibiotics, often leading to severe infections that are difficult to treat. Applications span various healthcare settings, including hospitals and outpatient clinics, primarily addressing skin infections, pneumonia, and bloodstream infections. End-use sectors comprise healthcare facilities, pharmaceuticals, and biotechnology firms. Key growth factors include the rising prevalence of antibiotic-resistant infections and increasing healthcare expenditures, whereas advancements in molecular diagnostics and drug development further drive progress. Recent opportunities are found in the development of novel antibiotics and alternative therapies like bacteriophage treatment and immunotherapy, crucial due to mounting antibiotic resistance. Companies should explore partnerships with academic institutions for drug discovery and invest in AI-driven research to shorten development cycles. Limitations in the market include the high cost of drug development, potential regulatory hurdles, and the slow adaptability of healthcare systems to integrate new MRSA treatments. Economic challenges and price pressures from governments and healthcare providers also play a significant role. Innovation can be driven by focusing on developing multi-target drugs and leveraging biotechnology to enhance the efficacy of existing treatments. Moreover, enhancing infection control measures and patient education can minimize MRSA transmission, indirectly impacting market growth. The nature of the MRSA drugs market is dynamic, with rapid advancements in medical research contributing to a constantly evolving landscape. Strategic investment in R&D and embracing cutting-edge technology will be essential for companies to establish a strong foothold and respond effectively to emerging threats posed by MRSA.

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.21 billion
Forecast Year [2030] USD 3.22 billion
CAGR (%) 6.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Methicillin-Resistant Staphylococcus Aureus Drugs Market

The Methicillin-Resistant Staphylococcus Aureus Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of infections associated with methicillin-resistant staphylococcus aureus
    • Rising investment in healthcare sector by private & public sector
  • Market Restraints
    • Fluctuating cost of raw materials used in methicillin-resistant staphylococcus aureus drugs formulations
  • Market Opportunities
    • Ongoing research & development activities to develop novel methicillin-resistant staphylococcus aureus drugs
    • Increasing number of patent expiration of methicillin-resistant staphylococcus aureus drugs
  • Market Challenges
    • Time consuming and strict regulatory approval processes

Porter's Five Forces: A Strategic Tool for Navigating the Methicillin-Resistant Staphylococcus Aureus Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Methicillin-Resistant Staphylococcus Aureus Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Methicillin-Resistant Staphylococcus Aureus Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

A detailed market share analysis in the Methicillin-Resistant Staphylococcus Aureus Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Methicillin-Resistant Staphylococcus Aureus Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Methicillin-Resistant Staphylococcus Aureus Drugs Market

A strategic analysis of the Methicillin-Resistant Staphylococcus Aureus Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Methicillin-Resistant Staphylococcus Aureus Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Aridis Pharmaceuticals Inc., Armata Pharmaceuticals, Inc., AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bausch Health Companies Inc., Baxter International Inc., Becton, Dickinson and Company, Cardinal Health, Inc., Cumberland Pharmaceuticals Inc., Debiopharm SA, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, GlaxoSmithKline PLC, Innovation Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Nabriva Therapeutics GMBH, Novartis AG, Paratek Pharmaceuticals, Inc., Pfizer Inc., R-Biopharm AG, Shionogi Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries ltd, and Theravance Biopharma, Inc..

Market Segmentation & Coverage

This research report categorizes the Methicillin-Resistant Staphylococcus Aureus Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Agent Type, market is studied across Ceftaroline, Daptomycin, Linezolid, Telavancin, and Vancomycin.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Sales Channel, market is studied across Offline and Online. The Offline is further studied across Hospitals Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of infections associated with methicillin-resistant staphylococcus aureus
      • 5.1.1.2. Rising investment in healthcare sector by private & public sector
    • 5.1.2. Restraints
      • 5.1.2.1. Fluctuating cost of raw materials used in methicillin-resistant staphylococcus aureus drugs formulations
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research & development activities to develop novel methicillin-resistant staphylococcus aureus drugs
      • 5.1.3.2. Increasing number of patent expiration of methicillin-resistant staphylococcus aureus drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Time consuming and strict regulatory approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Agent Type: Evolving adoption of daptomycin for effective treatment of MRSA
    • 5.2.2. Sales Channel: Expanding preference towards online channels due to easy access
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Agent Type

  • 6.1. Introduction
  • 6.2. Ceftaroline
  • 6.3. Daptomycin
  • 6.4. Linezolid
  • 6.5. Telavancin
  • 6.6. Vancomycin

7. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.2.1. Hospitals Pharmacies
    • 8.2.2. Retail Pharmacies
  • 8.3. Online

9. Americas Methicillin-Resistant Staphylococcus Aureus Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. UK Government's Strategic Investment in Global AMR Surveillance, Strengthening Health Systems Across Asia and Africa
    • 12.3.2. Basilea Seeks FDA Approval for New MRSA-Fighting Antibiotic Ceftobiprole
    • 12.3.3. BARDA's Strategic Funding Initiative for Melinta Therapeutics to Enhance Pediatric Antibiotic Access
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Aridis Pharmaceuticals Inc.
  • 3. Armata Pharmaceuticals, Inc.
  • 4. AstraZeneca PLC
  • 5. Basilea Pharmaceutica Ltd.
  • 6. Bausch Health Companies Inc.
  • 7. Baxter International Inc.
  • 8. Becton, Dickinson and Company
  • 9. Cardinal Health, Inc.
  • 10. Cumberland Pharmaceuticals Inc.
  • 11. Debiopharm SA
  • 12. Dr. Reddy's Laboratories Ltd.
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fresenius Kabi AG
  • 15. GlaxoSmithKline PLC
  • 16. Innovation Pharmaceuticals Inc.
  • 17. Johnson & Johnson Services, Inc.
  • 18. Lupin Limited
  • 19. Merck & Co., Inc.
  • 20. Nabriva Therapeutics GMBH
  • 21. Novartis AG
  • 22. Paratek Pharmaceuticals, Inc.
  • 23. Pfizer Inc.
  • 24. R-Biopharm AG
  • 25. Shionogi Inc.
  • 26. Takeda Pharmaceutical Company Limited
  • 27. Teva Pharmaceutical Industries ltd
  • 28. Theravance Biopharma, Inc.

LIST OF FIGURES

  • FIGURE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TELAVANCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 190. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023